Cargando…
Characterization of unusual iAMP21 B‐lymphoblastic leukemia (iAMP21‐ALL) from the Mayo Clinic and Children's Oncology Group
Acute lymphoblastic leukemia (B‐ALL) with intrachromosomal amplification of chromosome 21 (iAMP21‐ALL) represents a recurrent high‐risk cytogenetic abnormality and accurate identification is critical for appropriate clinical management. Identification of iAMP21‐ALL has historically relied on fluores...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549522/ https://www.ncbi.nlm.nih.gov/pubmed/35771717 http://dx.doi.org/10.1002/gcc.23084 |
_version_ | 1784805690580140032 |
---|---|
author | Koleilat, Alaa Smadbeck, James B. Zepeda‐Mendoza, Cinthya J. Williamson, Cynthia M. Pitel, Beth A. Golden, Crystal L. Xu, Xinjie Greipp, Patricia T. Ketterling, Rhett P. Hoppman, Nicole L. Peterson, Jess F. Harrison, Christine J. Akkari, Yassmine M. N. Tsuchiya, Karen D. Shago, Mary Baughn, Linda B. |
author_facet | Koleilat, Alaa Smadbeck, James B. Zepeda‐Mendoza, Cinthya J. Williamson, Cynthia M. Pitel, Beth A. Golden, Crystal L. Xu, Xinjie Greipp, Patricia T. Ketterling, Rhett P. Hoppman, Nicole L. Peterson, Jess F. Harrison, Christine J. Akkari, Yassmine M. N. Tsuchiya, Karen D. Shago, Mary Baughn, Linda B. |
author_sort | Koleilat, Alaa |
collection | PubMed |
description | Acute lymphoblastic leukemia (B‐ALL) with intrachromosomal amplification of chromosome 21 (iAMP21‐ALL) represents a recurrent high‐risk cytogenetic abnormality and accurate identification is critical for appropriate clinical management. Identification of iAMP21‐ALL has historically relied on fluorescence in situ hybridization (FISH) using a RUNX1 probe. Current classification requires ≥ five copies of RUNX1 per cell and ≥ three additional copies of RUNX1 on a single abnormal iAMP21‐chromosome. We sought to evaluate the performance of the RUNX1 probe in the identification of iAMP21‐ALL. This study was a retrospective evaluation of iAMP21‐ALL in the Mayo Clinic and Children's Oncology Group cohorts. Of 207 cases of iAMP21‐ALL, 188 (91%) were classified as “typical” iAMP21‐ALL, while 19 (9%) cases were classified as “unusual” iAMP21‐ALL. The “unusual” iAMP21 cases did not meet the current definition of iAMP21 by FISH but were confirmed to have iAMP21 by chromosomal microarray. Half of the “unusual” iAMP21‐ALL cases had less than five RUNX1 signals, while the remainder had ≥ five RUNX1 signals with some located apart from the abnormal iAMP21‐chromosome. Nine percent of iAMP21‐ALL cases fail to meet the FISH definition of iAMP21‐ALL demonstrating that laboratories are at risk of misidentification of iAMP21‐ALL when relying only on the RUNX1 FISH probe. Incorporation of chromosomal microarray testing circumvents these risks. |
format | Online Article Text |
id | pubmed-9549522 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95495222022-12-30 Characterization of unusual iAMP21 B‐lymphoblastic leukemia (iAMP21‐ALL) from the Mayo Clinic and Children's Oncology Group Koleilat, Alaa Smadbeck, James B. Zepeda‐Mendoza, Cinthya J. Williamson, Cynthia M. Pitel, Beth A. Golden, Crystal L. Xu, Xinjie Greipp, Patricia T. Ketterling, Rhett P. Hoppman, Nicole L. Peterson, Jess F. Harrison, Christine J. Akkari, Yassmine M. N. Tsuchiya, Karen D. Shago, Mary Baughn, Linda B. Genes Chromosomes Cancer Research Articles Acute lymphoblastic leukemia (B‐ALL) with intrachromosomal amplification of chromosome 21 (iAMP21‐ALL) represents a recurrent high‐risk cytogenetic abnormality and accurate identification is critical for appropriate clinical management. Identification of iAMP21‐ALL has historically relied on fluorescence in situ hybridization (FISH) using a RUNX1 probe. Current classification requires ≥ five copies of RUNX1 per cell and ≥ three additional copies of RUNX1 on a single abnormal iAMP21‐chromosome. We sought to evaluate the performance of the RUNX1 probe in the identification of iAMP21‐ALL. This study was a retrospective evaluation of iAMP21‐ALL in the Mayo Clinic and Children's Oncology Group cohorts. Of 207 cases of iAMP21‐ALL, 188 (91%) were classified as “typical” iAMP21‐ALL, while 19 (9%) cases were classified as “unusual” iAMP21‐ALL. The “unusual” iAMP21 cases did not meet the current definition of iAMP21 by FISH but were confirmed to have iAMP21 by chromosomal microarray. Half of the “unusual” iAMP21‐ALL cases had less than five RUNX1 signals, while the remainder had ≥ five RUNX1 signals with some located apart from the abnormal iAMP21‐chromosome. Nine percent of iAMP21‐ALL cases fail to meet the FISH definition of iAMP21‐ALL demonstrating that laboratories are at risk of misidentification of iAMP21‐ALL when relying only on the RUNX1 FISH probe. Incorporation of chromosomal microarray testing circumvents these risks. John Wiley & Sons, Inc. 2022-07-19 2022-12 /pmc/articles/PMC9549522/ /pubmed/35771717 http://dx.doi.org/10.1002/gcc.23084 Text en © 2022 The Authors. Genes, Chromosomes and Cancer published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Koleilat, Alaa Smadbeck, James B. Zepeda‐Mendoza, Cinthya J. Williamson, Cynthia M. Pitel, Beth A. Golden, Crystal L. Xu, Xinjie Greipp, Patricia T. Ketterling, Rhett P. Hoppman, Nicole L. Peterson, Jess F. Harrison, Christine J. Akkari, Yassmine M. N. Tsuchiya, Karen D. Shago, Mary Baughn, Linda B. Characterization of unusual iAMP21 B‐lymphoblastic leukemia (iAMP21‐ALL) from the Mayo Clinic and Children's Oncology Group |
title | Characterization of unusual iAMP21 B‐lymphoblastic leukemia (iAMP21‐ALL) from the Mayo Clinic and Children's Oncology Group |
title_full | Characterization of unusual iAMP21 B‐lymphoblastic leukemia (iAMP21‐ALL) from the Mayo Clinic and Children's Oncology Group |
title_fullStr | Characterization of unusual iAMP21 B‐lymphoblastic leukemia (iAMP21‐ALL) from the Mayo Clinic and Children's Oncology Group |
title_full_unstemmed | Characterization of unusual iAMP21 B‐lymphoblastic leukemia (iAMP21‐ALL) from the Mayo Clinic and Children's Oncology Group |
title_short | Characterization of unusual iAMP21 B‐lymphoblastic leukemia (iAMP21‐ALL) from the Mayo Clinic and Children's Oncology Group |
title_sort | characterization of unusual iamp21 b‐lymphoblastic leukemia (iamp21‐all) from the mayo clinic and children's oncology group |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549522/ https://www.ncbi.nlm.nih.gov/pubmed/35771717 http://dx.doi.org/10.1002/gcc.23084 |
work_keys_str_mv | AT koleilatalaa characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT smadbeckjamesb characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT zepedamendozacinthyaj characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT williamsoncynthiam characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT pitelbetha characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT goldencrystall characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT xuxinjie characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT greipppatriciat characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT ketterlingrhettp characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT hoppmannicolel characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT petersonjessf characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT harrisonchristinej characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT akkariyassminemn characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT tsuchiyakarend characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT shagomary characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup AT baughnlindab characterizationofunusualiamp21blymphoblasticleukemiaiamp21allfromthemayoclinicandchildrensoncologygroup |